<DOC>
	<DOCNO>NCT01260454</DOCNO>
	<brief_summary>Subcutaneous treprostinil ( Remodulin ) effective therapy pulmonary arterial hypertension , life threaten disease lung blood vessel . Unfortunately , treprostinil irritate skin many patient experience intense pain infusion site first 7-10 day place new subcutaneous infusion site . Qutenza FDA approve formulation 8 % capsaicin approve treatment post-herpetic neuralgia , painful skin condition . The investigator hypothesize pretreatment area skin Qutenza would decrease pain associated new treprostinil infusion site . The investigator hope Qutenza decrease intensity pain duration pain patient place new treprostinil infusion site . In initial study , investigator provide Qutenza open-label , unblinded fashion ask patient rate pain use diary tool already comfortable .</brief_summary>
	<brief_title>The Qutenza Patch Treatment Disabling Treprostinil ( Remodulin ) Infusion Site Pain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Pulmonary Hypertension Using subcutaneous treprostinil Already participate subject prospective study infusion site pain Has document debilitate pain ( 6/10 great ) study site change Uncontrolled hypertension Recent stroke myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Qutenza</keyword>
	<keyword>Capsaicin</keyword>
	<keyword>Remodulin</keyword>
	<keyword>Treprostinil</keyword>
</DOC>